SLE is the most common form of lupus and is also called lupus. It is a chronic, autoimmune disease with signs and symptoms that can last for six months or for many years. It can affect any part of the body, such as the skin, joints, and organs (LFA, 2012). SLE occurs when the immune system produces autoantibodies, which attack and destroy healthy tissues in the body rather than foreign infectious agents. These autoantibodies cause inflammation, pain, and damage. It is also known as a disease of flare-ups and remissions and can range from mild to life threatening in severity. No cure for SLE yet exists.
TechNavio's analysts forecast the Global SLE Drugs market to grow at a CAGR of 22.41 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global SLE Drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of SLE that are available in the market.
TechNavio's report, the Global SLE Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA; it covers the Global SLE Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019
Technavio recognizes the following companies as the key players in Global Systemic Lupus Erythematosus (SLE) Drugs Market 2015-2019: Anthera Pharmaceuticals Inc, BMS Co, GSK plc, ImmuPharma plc, Merck Serono SA and UCB SA.
Other Prominent Vendors in the market are: Amgen, HGS, Immunomedics, Johnson & Johnson, MedImmune, Sanofi and Teva Pharmaceutical Industries
Commenting on the report, an analyst from Technavio’s team said: “Knowledge about the diagnosis of SLE and its treatment is growing in Europe and Asia, areas where the disease is more prevalent. In addition, numerous public awareness campaigns aimed at increasing awareness levels are also being conducted. For instance, LFA has been implementing various projects to increase federal support for lupus research and services to assist people and families affected by lupus. Similarly, SLE Lupus Foundation's program provides support services to patients and their families to cope with lupus.”
According to the report, the high prevalence of autoimmune disease is a major contributor to the growth of the market. The number of people being diagnosed with SLE has been on the rise. Therefore, the demand for drugs is also increasing.
Further, the report states that the complex etiology of the disease is a major challenge in the market.
Anthera Pharmaceuticals Inc, BMS Co, GSK plc, ImmuPharma plc, Merck Serono SA, UCB SA, Amgen, HGS, Immunomedics, Johnson & Johnson, MedImmune, Sanofi, Teva Pharmaceutical Industries